TITLE

Akzo to Float 20%-30% of Pharma Business in Planned IPO; Shareholders Vote Next Month

AUTHOR(S)
Young, Ian
PUB. DATE
August 2006
SOURCE
Chemical Week;8/23/2006, Vol. 168 Issue 28, p11
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article announces the plan of Akzo Nobel to float 20% to 30% of its combined pharmaceutical and veterinary medicines business under a previously announced initial public offering (IPO). Shareholders will vote on plans to split Akzo into two separately quoted companies. Organon BioSciences will be listed on the Euronext stock exchange in Amsterdam, Netherlands following the IPO.
ACCESSION #
22215449

 

Related Articles

  • Akzo Nobel to IPO Organon. Sinclair, Neil // Chemical Market Reporter;8/21/2006, Vol. 270 Issue 6, p12 

    The article reports that Akzo Nobel, a coatings and health care group, will sell 20 to 30 percent of its Organon Biosciences unit through initial public offering (IPO) in 2007 on the Euronext exchange in Amsterdam, Netherlands. Selling of Organon unit comes after the company disclosed in...

  • IPO of Organon BioSciences Imminent. van der Zanden, Tim // China Chemical Reporter;3/6/2007, Vol. 18 Issue 7, p10 

    The article focuses on an announcement made by Akzo Nobel NV regarding its plan of launching an initial public offering (IPO) for the firm Organon BioSciences. A listing of about 20 to 30 percent of Organon BioSciences' shares on Euronext Amsterdam was done by Akzo. According to Hans Wijers,...

  • 5-MINUTE NEWS WATCH.  // ICIS Chemical Business Americas;2/19/2007, Vol. 271 Issue 7, p7 

    The article presents news briefs related to the chemical industry as of February 2007. Akzo Nobel plans to conduct an initial public offering (IPO) for 20% to 30% shares of Organon BioSciences on the Euronext exchange. Epichem has been acquired by Sigma Aldrich for $60 million. Merck has decided...

  • Akzo Nobel/Schering-Plough: good deal all round.  // PharmaWatch: Monthly Review;Apr2007, Vol. 6 Issue 4, p16 

    The article presents information on Akzo Nobel NV selling its healthcare business unit, Organon BioSciences NV, to Schering-Plough Corp. for $14 billion cash. It states that the deal allows Akzo Nobel to conduct acquisitions of its own as well as expansion into non-pharmaceutical markets. It...

  • …but it won't rush into purchases. Jagger, Anna // ICIS Chemical Business;6/18/2007, Vol. 2 Issue 71, p44 

    The article reports on the decision of Akzo Nobel not to rush into purchases following its divestment of Organon BioSciences (OBS), according to CEO Hans Wijers. Wijers states that potential acquisition targets would need to fit strategically with the existing portfolio and create value for...

  • Akzo's Chemicals Enter a New Era. Young, Ian // Chemical Week;11/1/2006, Vol. 168 Issue 36, p16 

    The article reports on the decision of Azko Nobel to become a manufacturer of chemicals and coatings after the split-off of its pharmaceuticals business Organon BioSciences (OBS) according to Akzo CEO Hans Wijers. It says that the separation of OBS follows after the completion of a major...

  • Akzo Nobel to sell Organon. Liming, Keith Tan; Ovrebekk, Hilde // ICIS Chemical Business Americas;3/19/2007, Vol. 271 Issue 11, p14 

    The article discusses the plan of Akzo Nobel to sell its stake in Organon BioSciences (OBS) to pharmaceutical group Schering-Plough. The deal, which is estimated at $14.5 billion, is expected to be closed in the second quarter of 2007. The deal increases the price of Akzo stock by 16 percent....

  • Akzo Nobel will accelerate growth. Baker, John // ICIS Chemical Business;2/19/2007, Vol. 2 Issue 54, p5 

    The article reports on the plan of Akzo Nobel to accelerate its growth as a focused coatings and chemicals business. The firm confirmed that it will begin the spin-off of its Organon BioSciences unit by the end of March 2007. Akzo board member Leif Darner emphasized that the company has a clear...

  • EUROPE IN BRIEF. Robinson, Simon // ICIS Chemical Business;9/18/2006, Vol. 1 Issue 35, p11 

    The article offers news briefs on the petrochemical industry in Europe. The oxxynova dimethyl terephthalate business of Degussa is being sold by the company to part of the capital investment firm Arques Group for € 22 million. Shareholders of Akzo Nobel have approved splitting the firm...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics